GlaxoSmithKline plc (the ' Company ')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms V Whyte |
|||
b) |
Position/status |
Company Secretary |
|||
c) |
Initial notification/ amendment |
Initial Notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Descriptionofthe financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b) |
Nature ofthe transaction |
Transfer of 10,726 Ordinary Shares between accounts for nil consideration.
|
|||
c) |
Price(s)and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£0.00 |
10,726 |
|
||
|
|
|
|
||
d) |
Aggregated information |
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date ofthe transaction |
2021-02-16 |
|||
f) |
Placeofthe transaction
|
N/A |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms V Whyte | |||
b) | Position/status | Company Secretary | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Descriptionofthefinancial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Natureofthetransaction | Transfer of 10,870 Ordinary Shares to spouse for nil consideration.
| |||
c) | Price(s)and volume(s) |
| Price(s) | Volume(s) |
|
| £0.00 | 10,870 |
| ||
|
|
|
| ||
d) | Aggregatedinformation | N/A (single transaction) | |||
AggregatedvolumePrice |
| ||||
e) | Date ofthetransaction | 2021-02-18 | |||
f) | Placeofthe transaction
| N/A |
| Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr I Whyte | |||
b) | Position/status | PCA of Ms V Whyte (Company Secretary) | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Descriptionofthefinancial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Natureofthetransaction | Receipt of 10,870 Ordinary Shares from spouse for nil consideration. | |||
c) | Price(s)and volume(s) |
| Price(s) | Volume(s) |
|
| £0.00 | 10,870 |
| ||
|
|
|
| ||
d) | Aggregatedinformation | N/A (single transaction) | |||
AggregatedvolumePrice |
| ||||
e) | Date ofthetransaction | 2021-02-18 | |||
f) | Placeofthe transaction
| N/A |